Promomed Group receives patent for injectable form of antiviral drug Areplivir® (favipiravir)
Promomed Group received a patent for an invention that protects a drug product for COVID-19 Areplivir® in three forms for parenteral administration – lyophilizate, concentrate and powder.
Promomed was the first in the world to develop a complex unique process for dissolving practically insoluble favipiravir and preparing stable injection forms based on it.
The injectable form of favipiravir is characterized not only by 100% bioavailability, but also by more intensive penetration and distribution in cells, longer retention of therapeutic concentration in tissues, and the possibility of using this form in patients who cannot receive tablets. This is especially important when it is necessary to stop the critical development of the disease and achieve a quick and maximum effect in already hospitalized patients.
In a multicenter comparative clinical study led by Dmitry Pushkar, Academician of the Russian Academy of Sciences, Doctor of Medical Sciences, Professor, member of the academic consortium of the academic community for the study of COVID-19, Areplivir®in form for parenteral administration demonstrated efficacy compared to standard therapy in hospitalized patients and safety.
The first original domestic antiviral direct action drug Areplivir® for intravenous administration received a marketing authorization on November 12, 2021, and then was included in the updated, fourteenth, revision of the interim guidelines “Prevention, diagnosis and treatment of a new coronavirus infection (COVID-19)” approved by the Russian Ministry of Health. On the same day, the first batch of medicinal product was shipped from the Biokhimik plant (member of Promomed Group).